The CRISPR/Cas9 genome editing platform is a promising technology to correct the genetic basis of hereditary diseases. gene editing in DMD individual myoblasts dystrophin Sennidin A expression is usually restored Human dystrophin is also detected after transplantation of genetically corrected individual cells into immunodeficient mice. Importantly the unique multiplex gene editing capabilities of the CRISPR/Cas9… Continue reading The CRISPR/Cas9 genome editing platform is a promising technology to correct